The master dealmaker is back: David Hung takes the helm at Vivek Ramaswamy's Axovant
David Hung earned his spurs as a master dealmaker in biotech, blazing through a string of major partnerships for good (and bad) drugs before selling Medivation at auction for a whopping $14 billion. Now he’s back, joining hands with one of the brightest financial engineers in the business, as CEO of Vivek Ramaswamy’s Axovant.
Ramaswamy turned heads and raised more than a few eyebrows when he snagged a failed Alzheimer’s drug from GlaxoSmithKline for $5 million upfront and then made it the central feature in a record-setting biotech IPO for Axovant $AXON. Since then, Ramaswamy has been wheeling and dealing himself, setting up more companies as well as another IPO for Myovant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.